Colorectal cancer: are genetic and molecular biology researches reflected enough in the patient management?

Abstract

Nowadays, the results of clinical translational researches reflecting in the management of colorectal cancer patients are limited with usa of antibody therapy and detection of KRAS mutation determining the response to antibody treatment. However, in the near future, the new molecular markers are expected to enter into clinical usa with the results of these studies. In this review, the genetic and epigenetic risk factors which play a role in the development of colorectal cancer, molecular diagnostic and prognostic markers, molecular- targeted treatments and promising molecules that are critical in determining the response to the therapy will be examined.